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Background: The EC-funded project SPIDIA is aimed to develop evidence-based quality guidelines for the
pre-analytical phase of blood samples used for DNA molecular testing. To this purpose, a survey and a
pan-European External Quality Assessment (EQA) were implemented.
Methods: SPIDIA facility sent to all the participants the same blood sample to be processed without time or
temperature limitation. DNA quality parameters performed at SPIDIA facility included: UV spectrophotometric
analysis of DNA purity and yield, PCR interferences study by Kineret software and DNA integrity analysis by
pulsed field gel electrophoresis.
Results: 197 applications have been collected from 30 European countries. A high variability of DNA fragmentation
was observed whereas purity, yield and PCR interferences had a narrow distribution within laboratories. A signifi-
cant difference between the RNase P single copy gene quantity obtained in the DNA samples extracted with the
precipitation-based method respect to those obtained with beads and column-based methods was observed.
Conclusions: The results of this study will be the basis for implementing a second pan-European EQA and the re-
sults of both EQAswill be pooled andwill provide the basis for the implementation of evidence-based guidelines
for the pre-analytical phase of DNA analysis of blood samples.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Molecular biology-based procedures have opened new perspectives
in diagnosis, prognosis and treatments of disease, however the level
of standardization of these technologies is often lower than in other
areas of laboratory medicine [1–3]. For clinical laboratories performing
molecular diagnostics, participation in proficiency testing/quality
assessment programs (PT/EQA) is essential [4–7]. Disease-specific or
methodological PT/EQA protocols are now available in genetic testing
[8–11] and microbiology [12–14].
To have the greatest value, PT/EQA challenge samples should be
designed to evaluate laboratory performance of the entire diagnostic
workflow including the pre-analytical, analytical and post-analytical
phases [15]. To meet this requirement, the PT/EQA samples should
be a clinical specimen which most closely represents what is actuallyal, Experimental and Clinical
9 Florence, Italy. Tel.: +39 055
alentacchi).
rights reserved.tested in a clinical laboratory and permits the evaluation of all phases
of the testing process, including the DNA extraction step [16]. It is,
however, often difficult for formal PT/EQA programs to obtain suffi-
cient quantities of appropriate, high-quality, safe, homogeneous and
stable clinical samples (e.g. a whole blood specimen) to supply all of
the laboratories participating in any given PT exercise [16,17]. Conse-
quently, most PT/EQA programs for molecular diagnostics employ
highly purified extracted DNA samples rather than actual clinical
specimens. In this instance, therefore, the participating laboratories can-
not be evaluated for their proficiency in performing the pre-analytical
phase of the analysis. Since it is known that DNAmolecular characteristics
can change in clinical samples during collection, transport and storage
[18,19], the lack of systematic investigation of the effects of pre-
analytical factors on analytical performance represents a challenge for
molecular pathologists. It is therefore imperative for the proper imple-
mentation of future and current molecular diagnostic assays that stan-
dards, guidelines and new stabilization technologies are developed for
pre-analytical specimen handling which yield the best possible analytical
result.
SPIDIA (www.spidia.eu), a four-year integrated project funded by
the European Commission, aims to develop quality guidelines and
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process with the net result of improving the stabilization and
handling of biological samples. An important part of this project is
the implementation of quality assessment schemes (EQAs) for the
collection, transport and processing of blood samples for RNA and
DNA-based analysis.
Here we report the description and the results of SPIDIA DNA EQA:
a large, pan- European trial, involving 197 laboratories from 30 coun-
tries. The aim of this EQA was to investigate the influence of blood
collection and specimen shipment on genomic DNA quality and quanti-
ty. To date, this aspect of molecular diagnostics has been a poorly inves-
tigated [20]. To carry out the PT, the SPIDIA reference laboratory,
Florence, Italy, sent the same blood sample to all participants for pro-
cessing. During this phase of the study, no time or temperature limita-
tions were imposed, but laboratories were asked to record the date of
specimen processing (i.e. DNA extraction) and the extraction procedure.
Purified DNA from each of the participating laboratories was then
shipped back to the SPIDIA reference laboratory. DNA quality parameters
performed at the SPIDIA facility included UV spectrophotometric analysis
of DNA purity and yield. In addition, we further analysed the quality of
DNA for PCR inhibition, performance in a qPCR assay. DNA integrity was
also determined on all samples using pulsed field gel electrophoresis.2. Materials and methods
2.1. Collection of applications
The announcement of the SPIDIA-DNA EQA was published on the
EFLM web site (www.efcclm.org). Dedicated websites were created
containing the description of the SPIDIA project (www.spidia.eu), the
proposed protocols and the application form together with a question-
naire page (www.efcclm.org).
Details on the content of these web pages are reported as Supple-
mental data: the Questionnaire (Supplemental 1), the protocols de-
scribing the procedures (Supplemental 2) to follow for blood/DNA
extraction/storage, and the Results forms (Supplemental 3) to record
the data and information used for blood samples storage/extraction/
analysis. The participants recorded detailed information about their
standard procedure usually used in the laboratory practice from
"blood collection to DNA analysis and storage" (Supplemental 1).2.2. DNA1, 2 and 3 preparation, blood collection and shipment conditions
DNA was purified from a pool of 15 blood specimens collected in
tubes containing EDTA as the anticoagulant (BD Vacutainer, 367864,
BD). DNA was extracted using the PureGene kit (Qiagen).
After extraction, three DNA samples with different levels of yield
and purity were prepared: DNA1, 65.4 ng/μl, 1.82 A260/280 nm ratio;
DNA2, 17.28 ng/μl, 1.82 A260/280 nm ratio, and DNA3, 84.5 ng/μl,
1.32 A260/280 nm ratio.
Blood (350 ml) was collected from each of two consented, adult
donors who tested negative for HIV, HBV and HCV. Blood was collect-
ed using classical phlebotomy procedure in CPDA-containing blood
collection bag. After collection, blood was pooled in a sterilized flask,
gently stirred, and immediately aliquoted into 2 ml polypropylene
tubes (BioClass T334-2 s). In addition to one blood tube containing
1.2 ml of the pooled blood sample, participating laboratories received
three pre-extracted DNA (DNA1, DNA2, DNA3), one empty vial to be
used to send the extracted DNA (DNA4) back to the SPIDIA facility
for analysis. The shipping was performed by an international courier
the day after the blood collection, and the blood-containing tubes
were stored at 4 °C until packaging and shipment. Shipping boxes
contained a frozen soft gel ice pack to maintain cooled conditions
during shipping.2.3. Instructions for the participants
The participants received the box containing the three extracted
DNAs, blood sample and the instruction (Supplemental 2) for performing
the DNA extraction. The laboratories extracted DNA following their stan-
dard procedure under their ownhandling conditionswith no restrictions
concerning sample storage temperature or time to extraction.
2.4. Data reporting from participants
The participants recorded detailed information about the procedure
used during the DNA extraction phase fromwhole blood. This informa-
tion included date of sample arrival, date and time of DNA extraction,
storage temperature and elapsed times of blood sample and extracted
DNA, extraction protocol and spectrophotometric evaluation. All data
were recorded in the on-line Results form (Supplemental 3).
2.5. DNA shipment and storage conditions
After DNA extraction, the participants sent the DNA sample (DNA 4)
using the same shipping box in which they received the samples. All
shipments were sent to the SPIDIA facility where the DNA samples
were stored at−20 °C until analysis.
2.6. DNA quality parameters
The DNA quality parameters performed on DNA4 at the SPIDIA
facility included a UV spectrophotometric analysis of DNA purity and
yield, an analysis of DNA integrity by pulsed field gel electrophoresis
interpreted using ImageJ software (www.rsbweb.nih.gov/ij), quantifi-
cation of the RNase P single copy gene (Life Technologies) by qPCR,
and the evaluation of PCR inhibition by Kineret software (Labonnet).
2.6.1. Spectrophotometric analysis
DNA was quantified by a NanoDrop® 1000 UV spectrophotometer
(NanoDrop Technologies).
Spectrophotometric measurements were performed at 260,
280, and 320 nm. Absorption at 320 nm was used to subtract back-
ground absorption. DNA purity was calculated as absorbance ratio
R = (A260–A320)/(A280–A320) and DNA total yield as Q = (A260 – A320) ×
50 × dilution factor × elution volume/extracted blood volume(ng/
μl). Alternatively, when the reading at 320 nm was not reported
by participants, the absorbance ratio was calculated as R = A260/
A280 and RNA total yield as Q = A260 × 50 × dilution factor × elu-
tion volume/extracted blood volume (ng/μl).
2.6.2. Analysis of DNA integrity
The analysis of the DNA integrity was performed by combining the
pulsed field gel electrophoresis (PFGE) with ImageJ imaging soft-
ware in order to transform the experimental data (PFGE image) into
numerical form.
For Procedure used to analyzed th DNA4 integrity: the extracted
DNA was analyzed by PFGE performing the following protocol. The
corresponding picture was analyzed by ImageJ software in order to
define the maximum, minimum and peak (DIRVs). For pulsed field
gel electrophoresis, 800 ng of DNA separated on a 1% agarose gel
(Ultra Pure Agarose, Invitrogen), using 0.5× TBE buffer (45 mM Tris,
45 mM borate, 2.5 mM EDTA) and a CHEF DRII system (BioRad).
Low Range PFG Marker (2.03–194 kb; New England Biolabs) was
used as DNA size marker. Electrophoresis was performed for 16 h at
10 °C with 6 V/cm and a switch time of 1–12 s. The gel was stained
for 30 min using 0.5 μg/ml ethidium bromide solution and destained
for 1–2 h in distilled water. The gel image was documented with the
EASYWin32 system (Herolab) and, analyzed by ImageJ software. De-
tails of the ImageJ analysis are described in Supplemental Fig. 1.
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qPCR was performed using TaqMan RNase P gene Detection Re-
agents (Life technologies). For each sample, 1 μl of DNA4 was
added to 6.25 μl of 2× Universal PCR Master Mix (Life Technologies)
and to 0.625 μl of TaqMan RNase P Detection Reagents and 6.25 μl of
water for a final volume of 12.5 μl. The amount of each target gene
was evaluated in triplicate against a standard curve generated by se-
rial dilution (1:10) of a plasmid (from 107 to 101 pg/tube) containing
the RNaseP target sequence. Samples and standards were subjected
to 40 amplification cycles at 95 °C for 15 s and 60 °C for 60 s after
10 min incubation time at 95 °C in the 7900 HT fast Real-Time PCR
System (Life Technolgies). After amplification, results were corrected
for the blood volume used for the DNA extraction and for the elution/
resuspension volume reported by the participants. The amplification ki-
netics obtained from the qPCR was used for the Kineret analysis in
order to evaluate the amplification kinetics of each sample in respect
to the other samples, which were used as “reference” value [21].
2.7. Statistical analysis and results interpretation
In the absence of known reference values for each of the factors in-
vestigated, wemeasured the consistency of a given participant's results
against all values excluding outliers (90%) of the results provided by
the other participants as previously described [22]. Briefly, a two-step
statistical procedure based on a distribution-free approach was
adopted in order to process the data corresponding to each of the
following variables: DNA purity (DNA1, 2, 3, 4), DNA concentration
(DNA1, 2, 3), DNA yield (DNA4), DIRVs (i.e. maximum, minimum
and peak - DNA4), concentration of RNase P (DNA4). The aims of
this procedure were to detect outliers and/or identify laboratories
with issues related to performance.
The first step in the analysis involved the computation of the 95th
bootstrap centile [23] of the distribution of the absolute value of the M
statistic [24]. This centilewas adopted as the threshold for detecting out-
liers. After removing the outliers from the distribution, the second step
was the identification of laboratories whose performance could still be
considered as outside the norm of most of the laboratories. This was
done by calculating specific bootstrap centiles from the outlier-free dis-
tribution. The number of bootstrap samples used was 1000 in each step.
This procedure allowed us to calculate robust control limits (one or
two sided) for the evaluation of the performance of each participant.
We used the 2.5th and the 97.5th bootstrap centile to identify the
lower and upper Action Limit (AL) and the 10th and 90th bootstrap
centile to identify the lower and the upper Warning Limit (WL) for all
the variables except for DNA yield, DIRVs and concentration of RNaseP
target sequence for which higher values indicate better performance.
For these latter we used the 5th and the 20th bootstrap centile to iden-
tify the one-sided AL andWL, respectively. According to these limits the
performance of each participant was classified as follows:
Out of control: if the value exceeds the upper or the lower AL or if
the value was below the one-sided AL.
Warning: if the valuewas between the upper AL andWLor between
the lower AL and WL, or between the one-sided WL and AL.
In control: if the value was between the lower and the upper WL,
or exceeds the one-sided WL.
The analysis and interpretation of the qPCR kinetics were
performed as previously described [22].
3. Results
3.1. Applicant collection, recruitment and questionnaire information
197 applications have been collected from 30 different European
countries (Fig. 1 Panel A). A description of the structure of theapplicant laboratories is reported in Fig. 1, Panel B and their primary
applications for DNA analyses are shown in Fig. 1, Panel C. At
deadline, 183 laboratories (92.9%) had taken part in the SPIDIA DNA
EQA.
Analysis of the Questionnaire (Table 1) revealed that 90% of the
laboratories typically collect blood in K2EDTA tubes, and only 10% uti-
lize other types of blood collection tubes. The blood volume usually
collected by the participating laboratories range from 2.5 to 5 ml.
Forty-two per cent (42.2%) of the laboratories perform DNA extrac-
tion within 24 h of blood collection, whereas 43.3% extract DNA
within 48 h of collection. Moreover, approximately 60% of the partic-
ipating laboratories store blood at +4 °C prior to DNA extraction. Al-
most all laboratories utilize a commercial kit for DNA purification by a
silica-membrane-based procedure. About 80% of the participants
evaluate the DNA concentration after the extraction and almost all
(94.4%) use a spectrophotometer rather than fluorescent detection
dyes or other methods.
3.2. Report for the participants
At the SPIDIA facility resultant DNA samples were analyzed as de-
scribed in Materials and Methods, and the results were evaluated
using the statistical approach described above to produce an individual
report for each participant (See Appendix A for an example of one such
report). In the report, the distribution of all the data for each quality pa-
rameter was graphically displayed in a box-plot which depicted the AL
and theWL togetherwith a reddot indicating the individual value of the
DNA from that particular laboratory. A red box under each graph indi-
cated the classification of the laboratory's performance for this specific
parameter. A zoom window was also displayed for each box-plot to
aid in the visualization of the participant's result when the distribution
of the variables was highly skewed.
3.2.1. Spectrophotometric data: Purity and concentration of pre-extracted
DNAs
In Table A.1 (Appendix A), we report the spectrophotometric mea-
surement of DNA1, 2 and 3 provided by the participants. Sections A.2
and A.3 (Appendix A) show the box-plots of the distributions of the pu-
rity and concentration of pre-extracted DNA. The median purity values
are 1.86, 1.83 and 1.36 for DNA1, DNA2 and DNA3 respectively. Theme-
dianDNA concentration is: 67.28 ng/μl for DNA1, 18 ng/μl for DNA2 and
86.8 ng/μl for DNA3. The DNA3 shows the highest concentration-
related IQR (15.6) and the lowest IQR (0.06) in terms of purity.
3.2.2. Spectrophotometric data: Purity and quantity of DNA 4
In section B (Appendix A)we report the purity and quantity of DNA4
extracted from the blood sample sent to all participants. Tables B.1 and
B.2 (Appendix A) include the spectrophotometric measurement results
provided by the participants (left panel) and calculated by the SPIDIA
facility (right panel) together with details of sample handling times,
methods and reagents used by each participant.
Sections B.3 and B.4 (Appendix A) show the box-plots of the dis-
tributions of the DNA purity and quantity reported by the participants
(left panel) and obtained by the SPIDIA facility (right panel). In par-
ticular, the median value for the purity reported by the participants
is 1.81 (IQR: 0.21), whereas the median of the purity calculated by
SPIDIA is 1.93 (IQR: 0.19). The median DNA concentration obtained
by the participants is 19.67 ng/μl (IQR: 15.82) whereas the median
value obtained by SPIDIA is 18.99 ng/μl (IQR: 13.63). Of note was the
fact that both median and IQR values for DNA purity and DNA concen-
tration calculated by the participants are very similar to those obtained
by SPIDIA.
3.2.3. Integrity of DNA
This analysis was performed on DNA4 to verify DNA integrity by
molecular weight. Section C.1 (Appendix A) depicts an image of the
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Fig. 1. Distribution of participant laboratories (n = 197) through Europe (Panel A), affiliation (Panel B) and the main area of research (Panel C).
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each of the considered DIRVs (i.e. minimum, maximum and peak)
derived from the Image J analysis of the gel image (See Materials
and Methods section and Supplemental Fig 1). A graphic repre-
sentation of DIRV data from all participating laboratories is shown in
section C.3 (Appendix A). In particular, the median values were
2.28 kb, 80.62 kb, and 20.32 kb for minimum, maximum, and peak,
respectively.
3.2.4. qPCR and kinetics analysis
Section D.1 (Appendix A) shows a graphic representation of qPCR
results from all participating laboratories. The left panel shows
an evaluation of the total amount of DNA4 (median 132.86 ng/μl
blood) as determined by the RNase P single copy gene amplification.
The right panel summarizes the evaluation of the interferences
as determined by Kineret software analysis. The Kineret analysis was
performed on the amplification results obtained from qPCR amplification
of the RNAse P single copy gene (See Materials and methods).
3.2.5. Summary of the lab performance evaluation
Table G (Appendix A) summarizes the performance of the labora-
tories for DNA quality parameters. The table shows the results using
three colors: green if the performance is “in control”, yellow if the
performance is “warning” or “weak outlier”, and red if the performance
is “out of control” or “strong outlier”. When it was not possible to eval-
uate the performance due to a missing value, the word “missing” is
reported in the summary table with an explanation in the “comments”
column. All data are visually depicted as a radar graphwith performance
symbolized by a colored square (same colors as in the summary table)
and the distance between the colored square and the center of theradar graph indicates the performance (the further away from the
center, the worse is the performance).
3.2.6. Relationship between the DNA quantity and the extraction method
To explore the relationship between the RNase P gene quantity
and the extraction methods used by participants (categorized in
three categories: bead-, column- and precipitation-based method),
the Kruskal–Wallis test was adopted. On the basis of this analysis,
the amount of DNA extracted by using a precipitation-based method
(median value of 60.996 ng/μl blood) was significantly lower in compar-
ison to DNA extracted with either bead- (122.185 ng/μl blood) or silica
membrane column-based purification procedures (164.219 ng/μl blood)
(Fig. 2).
3.3. Overall performance of the laboratories participating in the RNA
SPIDIA EQA program
On the basis of the DNA quality parameters and the statistical ap-
proach used in this EQA program, for 65/183 laboratories (35.5%), the
performance was not critical (all parameters classified as “in control”
or “warning”). For 70/183 (38.3%) of participating laboratories, only
one quality parameter was “out of control and/or one or moremissing
data points. Two or more “out of control” quality parameters were
measured for the remaining 48/183 (26.2%), including one or more
missing data points (see Table 2).
4. Discussion
Molecular methods are todaywidely used in laboratorymedicine,
and tests for DNA in human genetics, hematology, molecular
Table 1
Questionnaire distribution frequencies: usual procedures used by participants labora-
tories (n = 108).
N %
1. In which tube do you usually perform blood collection?
KXEDTA 162 90
Na citrate 7 3.9
Li/Na heparine 6 3.3
PAX gene blood DNA 3 1.7
Other 2 1.1
2. How many milliliters of blood do you collect?
≤2.5 ml 35 19.4
2.5 ml b x ≤ 5 ml 101 56.1
5 ml b x b 10 ml 18 10.0
≥10 ml 26 14.5
3. How long is the time interval between the blood collection and theDNA extraction?
≤24 h 76 42.2
24 h b x ≤ 48 h 78 43.3
48 h b x b 72 h 3 1.7
≥72 h 19 10.6
Missing 4 2.2
4. At what temperature is the collected “whole blood” stored?
Room temperature 16 8.9
+4 °C 106 58.9
−20 °C 46 25.5
−80 °C 12 6.7
5. What is the procedure for blood extraction?
Do you use a kit procedure?
No 12 6.7
Yes 168 93.3
6.The DNA extraction is based on:
(on 168 laboratories performing DNA extraction by kit procedure):
Precipitation 17 10.1
Silica membrane 79 47.0
Magnetic beads 46 27.4
Missing 26 15.5
7. Do you evaluate the concentration of extracted DNA from blood?
No 37 20.6
Yes 143 79.4
8. What is the method?
(on 143 laboratories performing the evaluation of DNA concentration):
Fluorescent dyes 4 2.8
Spectrophotometric measurement 135 94.4
Other 3 2.1
Missing 1 0.7
9. If you use spectrophotometric measurement, specify the formula used to calculate
the DNA amount:
(on 135 laboratories performing the evaluation of DNA concentration by
spectrophotometric measurement):
(A260-A320) × 50 × dilution factor 20 14.7
A260 × 50 × dilution factor 65 47.8
Other 42 30.9
Missing 8 6.6
10. What kind of analysis do you usually perform on your extracted DNA from
blood?
Qualitative PCR 55 30.5
qPCR 38 21.1
Sequencing 19 10.6
Other 68 37.8
11. At what temperature do you usually store the extracted DNA from blood?
Room temperature 1 0.5
+4 °C 64 35.6
−20 °C 103 57.2
−80 °C 12 6.7
Bead-based Column-based Precipitation-based
Extraction method
Qu
an
tity
 R
Na
se
P 
[ng
/µl
 bl
oo
d]
0
100
200
300
400
500
600
700
800
900
Fig. 2. Box-plot of the RNase P quantification by qPCR. RNaseP gene quantity according to
extraction method categorized in bead- (N = 39), column- (N = 85) and precipitation-
(N = 21) based method. The amount of DNA extracted by using a precipitation-based
method was lower in comparison to DNA extracted with either bead- (Bonferroni
p-value = 0.02) or column-based method (Bonferroni p-value b0.01). Each box shows
the 25th and 75th percentiles, the horizontal line inside the box indicates the median,
and the limits of the twowhiskers correspond tominimum andmaximumof the different
distribution.
Table 2
Classification of the performance of the laboratories.
Categories N %
All in control or warning performance a 65 35.52
One out of control performance and/or one or more missing b 70 38.25
Two or more out of control performance with or without missing c 48 26.23
Total of participants laboratory 183 100.00
Description of the categories:
a all in control or warning performance: labs with all performances in control or
warning, without missing;
b one out of control performance and/or one or more missing: labs with only one out
of control (N = 35); labs with only one missing (N = 6) or only more than one miss-
ing (N = 18); labs with one out of control and one missing (N = 1); labs with one out
of control and more than one missing (N = 10);
c two ormore out of control performancewith or withoutmissing: labswith two out of
control with at least one missing (N = 3) or without missing (N = 17); labs with more
than two out of control with at least one missing (N = 8) or without missing (N = 20).
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in laboratorymedicine [23]. In the last few years, an adequate quality
assurance framework has been developed which is based on knowl-
edge acquired from specific surveys [6], implementation of quality
assessment and proficiency programs (www.cap.org; www.emqn.org;
www.dgkl.dc; www.eurogentest.org), and by the development of
method-specific guidelines [7,25].
Most of the available PT/EQA for molecular diagnostics are based
on the analytical phase of the test process, however. These schemesshould reflect clinically relevant challenges that incorporate all steps
of the testing process, including pre- and post-analytical components.
Here we report a description of a pan-European survey and the
implementation of an External Quality Assessment program focused
on the pre-analytical phase of handling and processing blood samples
for DNA analysis. The survey posed questions to participating labora-
tories aimed at determining what laboratory policies and practices
are in place for specimen handling, and respondents were requested
to provide information on blood sampling andDNAextraction protocols
(Table 1). A strong tendency to use commercially available extraction
kits (mainly silica membrane technology) was observed. The majority
of the laboratories collects blood in EDTA tubes and performs the eval-
uation of yield and quality of DNA by spectrophotometric UV analysis,
storing the extracted DNA at−20 °C. Other aspects of sample handling
and analysis protocols were more variable, such as the volume of blood
collected and the time interval between blood collection and DNA
extraction. The wide range of answers to these questions confirmed
the need to develop specimen handling and processing guidelines for
tests requiring DNA from whole blood.
Togetherwith the survey, SPIDIA also implemented anEQA program
focused on the pre-analytical phase of analyzing DNA in blood.We have
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provided reports to each participating laboratory which describes the
performance of the laboratory relative to results obtained by themajor-
ity of participants.
The distribution of pre-extracted DNAs (DNA1, DNA2, DNA3) quali-
ty and quantity results (see Appendix A; section A.2 and A.3) from
participating laboratories were very close to those expected (both in
samples with good and poor purity, or with high or low concentration)
showing that spectrophotometric analysis of purified DNA is a well-
standardized practice in the enrolled laboratories.
For DNA extracted by participants from the blood sample (DNA4)
sent to all laboratories (Appendix A, section B.3, B.4), the SPIDIA lab-
oratory determined a median value of purity close to 1.8, indicating
high-quality DNA, and a median yield of 20 ng/μl. There was a very
narrow distribution of DNA yields among the laboratories and only
a few outliers were observed.
The range of DNA integrity of DNA4 samples as determined by
pulsed field gel electrophoresis is still, somewhat objective owing to
the visual nature of the results (See Appendix A, section C.1), however
transformation of gel images into numerical results was productive.
Using this approach, we observed a high degree of variability in DNA
fragmentation from laboratory to laboratory, however, the effect of the
degree of fragmentation must be further investigated using techniques
such as long-range or multiplex PCR which were not within the scope
of this project. In the view of a second run, we developed an ad hoc algo-
rithm that combines the by-eye evaluation of the gel image from PFGE
with the ImageJ software output.
The study of PCR interference was based on Kineret software analy-
sis of the kinetics obtained using the RNase P single copy gene qPCR
quantification of the DNA4 samples (Appendix A; section D). Only a
few laboratories produced DNA which interfered in a PCR reaction.
We have then investigated if the values of the DNA quality param-
eters were influenced by the procedures and protocols (temperature,
volumes, timing) used by the participants for DNA extraction.
A significant difference between the RNase P single copy gene quan-
tity obtained in the DNA samples extracted with the precipitation-
based method respect to those obtained with bead- and column-based
methods was observed (Fig. 2). The same trendwas observed whenwe
analyzed the DNAUVquantity obtained vs. the extractionmethod (data
not shown).
This SPIDIA DNA program was specifically designed for the evalua-
tion of the pre-analytical phase ofmolecular diagnostic assays requiring
DNA from whole blood and not for the evaluation of laboratory perfor-
mance of a specific diagnostic test. In conducting this program, we
wanted to give participating laboratories useful information concerning
general DNA quality parameters and how their current policies and
procedures for sample handling affected DNA quality. Regarding theperformances of the participants, on the basis of the DNA quality pa-
rameters and of the statistical approach used in this EQA program,
only 35% of the participants had not critical performances (see
Table 2). This result seems due to both the highly variable protocol con-
ditions and the different extraction procedures used by the participat-
ing laboratories in performing the pre-analytical phase (see Table 1)
and the high number of the quality parameters investigated in this
study (n = 15, see Appendix A, G. Summary). However this does not
mean that the downstream results of those laboratories having critical
performances on the basis of our classification criteriawould be affected
by their “poor” DNA quality as downstream analysis was not the target
of our EQA. On the other hand this result confirms the need of dedicated
Guidelines which is the final goal of the SPIDIA project.5. Conclusions
The objective of the SPIDIA-DNA EQA programwas to obtain infor-
mation on pre-extracted and laboratory-extracted DNA quality when
participants followed the protocols and reagents in use in their own
laboratories and to correlate these results to pre-analytical variables
in order to develop general guidelines for molecular in vitro diagnos-
tics. In this study, we focused on the optimization of blood collection
and shipment together with recording more detailed information on
time and temperature between blood collection and DNA extraction.
This protocol allowed a more in-depth analysis of the critical aspects
of the pre-analytical phase. On the basis of the results of the first
SPIDIA DNA EQA we will develop a second run, with more stringent
pre-analytical conditions (i.e. shipping temperature, blood storage
temperature) for the implementation of Evidence-Based Guidelines
for the handling blood samples for cellular DNA-based analysis.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.cca.2013.05.012.Acknowledgments
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and language editing of this manuscript.A. Purity and Concentration of DNA1, DNA2 and DNA3 (pre-extracted DNAs)
A.1. Spectrophotometric data provided by your lab260 nm 280 nm 320 nm Purity Concentration (ng/μl) Dilution factorDNA1 0.042 0.023 0.005 1.826 105 50
DNA2 0.034 0.019 0.003 1.789 85 50
DNA3 0.042 0.028 0.004 1.5 102.5 50
280 F. Malentacchi et al. / Clinica Chimica Acta 424 (2013) 274–286A.2. Your lab ( ) versus overall distribution (N = 172) – Purity
In the figures the blue lines represent the Action Limits (ALs) and the gray lines represent the Warning Limits (WLs).
A.3. Your lab ( ) vs overall distribution (N = 174) – Concentration
In the figures the blue lines represent the Action Limits (ALs) and the gray lines represent the Warning Limits (WLs)
281F. Malentacchi et al. / Clinica Chimica Acta 424 (2013) 274–286B. Purity and Quantity of DNA4 (DNA extracted from blood)
B.1. Spectrophotometric data provided by your lab and by SPIDIA lab
260nm
Lab
280nm
Lab
320nm
Lab
Purity
Lab Lab
Purity
Spidia
Quantity (ng/µl)
Spidia
Dilution
factor
Extraction
vol. (ul)
Elution
vol. (ul)
Buffer
0.293 0.165 0.015 1.776 19.54 1.875 16.5 2 150 100 Elution solution 2
Quantity (ng/µl)
B.2. Additional information provided by your labExtraction Spectrophotometer Temperature of DNA storage Time interval (hours)producer supplier producer supplier arrival to
extractionextraction to
analysisarrival to
extractionextraction to
analysisbloodprep
ChemistryApplied Biosystems ABI
PRISM 6100
Nucleic Acid Prebiospec 1601 shimadzu 4 °C 4 °C 89.5 h 1 hB.3. Your lab ( ) versus overall distribution – Purity
282 F. Malentacchi et al. / Clinica Chimica Acta 424 (2013) 274–286B.4. Your lab ( ) versus overall distribution - Quantity
In the figures the blue line represents the Action Limit (AL) and the gray line represents the Warning Limit (WL).
C. Integrity of DNA4 (DNA extracted from blood)
C.1. Your lab ( ) - pulse field gel electrophoresis image
283F. Malentacchi et al. / Clinica Chimica Acta 424 (2013) 274–286C.2. ImageJ data of your labMinimum (kb) Maximum (kb) Peak (kb)0.967 112.105 20.012C.3. Your lab ( ) versus overall distribution (N = 157) – ImageJ data
In the figure the blue line represents the Action Limit (AL) and the gray line represents the Warning Limit (WL).
284 F. Malentacchi et al. / Clinica Chimica Acta 424 (2013) 274–286D. Quantification of RNaseP by real-time PCR on DNA4 and evaluation of interferences
D.1. Your lab ( ) versus overall distribution
285F. Malentacchi et al. / Clinica Chimica Acta 424 (2013) 274–286G. SummaryPerformance Missing Comments
DNA1 – Purity in control
DNA2 – Purity in control
DNA3 – Purity out of control
DNA1 – Concentration out of control
DNA2 – Concentration out of control
DNA3 – Concentration in control
DNA4 – Purity (Lab) in control
DNA4 – Purity (Spidia) in control
DNA4 – Quantity (Lab) in control
DNA4 – Quantity (Spidia) in control
DNA4 – Integrity (min.) warning
DNA4 – Integrity (max ) in control.
DNA4 – Integrity (peak) in control
DNA4 – RNaseP quant. in control
DNA4 – Interferences in controlThis report has been produced with the collaboration of the University of Florence (M.Pazzagli, S.Gelmini, C.Orlando, L.Simi,
F.Malentacchi), Fondazione IRCCS Istituto Nazionale dei Tumori of Milan (P.Verderio, S.Pizzamiglio, C.Ciniselli), QIAGEN (R.Wyrich,
C.Hartmann) and TATAA BIOCENTER (A.Tichopad).References
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